Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis.

ABSTRACT:

Objective

We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti-CD20 therapy on clinical and sub-clinical outcomes in multiple sclerosis.

Methods

Clinical information was collected prospectively on Research Electronic Data Capture. Patients with age ≥ 18 years old, confirmed diagnosis of multiple sclerosis, treatment with B-cell depleting drug (Rituximab and Ocrelizumab), and minimum follow-up of 12 months with at least 3 clinical visits and at least 3 infusions of medication were included and divided into an extended interval dosing group, a standard interval dosing group, and a converters group who switched from standard to extended interval dosing. Retinal measures were obtained using spectral domain Optical

SUBMITTER: El Ayoubi NK 

PROVIDER: S-EPMC12516248 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature